CHRM4
ENSG00000180720
Target class
GPCR
Chromosome
11
Approved drugs
5
Clinical candidates (approved and in development)
7
- Approved drugs
- 5
- Clinical candidates (approved and in development)
- 7
- Chemical probe available
- Yes
- Target name
- CHRM4
- Gene name
- Cholinergic receptor muscarinic 4
- Gene symbol
- CHRM4
- Protein name
- Muscarinic acetylcholine receptor M4
- Gene biotype
- Protein coding
- Gene family
- Cholinergic receptors muscarinic
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 17
- Protein localisation evidence grade
- Uncertain
- Highest tissue expression
- 13.23
- Tissue specificity (Gini)
- 0.75
- Tissue specificity (tau)
- 0.873
- KEGG gene identifiers
- hsa:1132
- Protein interaction confidence
- 0.82125
- Protein interaction partners
- 8
- R-HSA-390648
- R-HSA-418594
- End position
- 46391990
- Start position
- 46383589
- Chromosome
- 11
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein. Postsynaptic cell membrane
- Multi-pass membrane protein.
- Plasma membrane
- Tissue specificity (tau)
- 0.872617
- Expression inequality (Gini)
- 0.750339
Expression in transcripts per million
- Brain - Nucleus accumbens (basal ganglia)
- 13.23
- Brain - Caudate (basal ganglia)
- 12.96
- Testis
- 12.45
- Spleen
- 10.91
- Brain - Putamen (basal ganglia)
- 7.69
Expression in transcripts per million
- Brain - Nucleus accumbens (basal ganglia)13.23
- Brain - Caudate (basal ganglia)12.96
- Testis12.45
- Spleen10.91
- Brain - Putamen (basal ganglia)7.69
- Brain - Cortex7.64
- Brain - Frontal Cortex (BA9)7.11
- Small Intestine - Terminal Ileum4.96
- Brain - Anterior cingulate cortex (BA24)2.83
- Skin - Sun Exposed (Lower leg)2.83
- Colon - Sigmoid2.62
- Skin - Not Sun Exposed (Suprapubic)2.29
- Pituitary1.97
- Brain - Hippocampus1.45
- Brain - Amygdala1.36
- Colon - Transverse1.1
- Brain - Hypothalamus1.03
- Esophagus - Muscularis0.74
- Esophagus - Gastroesophageal Junction0.57
- Brain - Cerebellum0.53
- Brain - Cerebellar Hemisphere0.41
- Stomach0.4
- Cells - EBV-transformed lymphocytes0.33
- Breast - Mammary Tissue0.3
- Artery - Tibial0.29
And 29 more, listed on the interactive page.
- GO:0007165
- GO:0007166
- GO:0007213
Cellular components
- GO:0005886
- GO:0005515
- GO:0016907
catalepsy
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: catalepsy
- nervous system
- cardiovascular
PubMed 28216264lacrimation
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: lacrimation
- nervous system
- cardiovascular
PubMed 28216264exhaustion
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: exhaustion
- nervous system
- cardiovascular
PubMed 28216264frothing
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: frothing
- nervous system
- cardiovascular
PubMed 28216264increased salivation
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased salivation
- nervous system
- cardiovascular
PubMed 28216264decreased heart rate
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased heart rate
- nervous system
- cardiovascular
PubMed 28216264sweating
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: sweating
- nervous system
- cardiovascular
PubMed 28216264decreased pupil diameter
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased pupil diameter
- nervous system
- cardiovascular
PubMed 28216264decreased blood pressure
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased blood pressure
- nervous system
- cardiovascular
PubMed 28216264muscle cramps
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: muscle cramps
- nervous system
- cardiovascular
PubMed 28216264blurred vision
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: blurred vision
- nervous system
- cardiovascular
PubMed 28216264irritability
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: irritability
- nervous system
- cardiovascular
PubMed 28216264ptosis
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: ptosis
- nervous system
- cardiovascular
PubMed 28216264
receptor binding
Studies
- biochemical: NVS_GPCR_hM4, is one of one assay component(s) measured or calculated from the NVS_GPCR_hM4 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.
Biological samples
- cell-free
Evidence source
Related records
Trials (47)
- A Confirmatory Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
- A Dose Ascending, Study To Examine The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of GSK233705B.
- A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia
- A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
- A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
- A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
- A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis
- A Safety Study of BBI-4000 Gel in Pediatric Patients With Axillary Hyperhidrosis
- A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 Gel in Subjects With Palmar Hyperhidrosis
- A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
- A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK233705 In Healthy Volunteers.
- A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia
- A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
- A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)
- A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)
- A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia
- A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia
- A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects
- A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects.
- A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, Explore the Effect of Food After Multiple Doses of Selected Prototypes, and Evaluate Alternative Formulations of KarX and KarXT Following Single and Multiple Ascending Doses
Drugs (11)
- Afacifenacin Muscarinic acetylcholine receptor antagonist
- Darotropium Muscarinic acetylcholine receptor antagonist
- Darotropium bromide Muscarinic acetylcholine receptor antagonist
- Glycopyrronium Muscarinic acetylcholine receptor inhibitor
- Glycopyrronium tosylate Muscarinic acetylcholine receptor inhibitor
- Sofpironium Muscarinic acetylcholine receptor inhibitor
- Sofpironium bromide Muscarinic acetylcholine receptor inhibitor
- Terodiline Muscarinic acetylcholine receptor antagonist
- Terodiline hydrochloride Muscarinic acetylcholine receptor antagonist
- Xanomeline Muscarinic acetylcholine receptor M4 agonist
- Xanomeline tartrate Muscarinic acetylcholine receptor M4 agonist